Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The association of relatively low doses of interferon with an immunostimulant, isoprinosine, enhanced the antitumor effect of interferon. Each mouse was inoculated with 10(6) Crocker Tumor 180/TG cells. The best results were obtained when both interferon and isoprinosine were injected three times a week for 1 month. Under these conditions, the mean survival time increased from 26 days in the controls to 45 days in the interferon-treated group to 64 days when both agents were used. Isoprinosine alone had no effect. The final survival rate increased from 1 mouse out of 50 mice in the control group to 10 mice out of 50 in the interferon-treated groups and to 25 mice out of 50 with the combined treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0192-0561(79)90031-6 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!